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Introduction: Staphylococcus aureus (S. aureus) is an important causative pathogen in
human infections. The production of biofilms by bacteria is an important factor, leading to
treatment failures. There has been significant interest in assessing the possible relationship
10between the multidrug-resistant (MDR) status and the biofilm-producer phenotype in bac-
teria. The aim of our present study was to assess the biofilm-production rates in clinical
methicillin-susceptible S. aureus [MSSA] and methicillin-resistant S. aureus [MRSA] iso-
lates from Hungarian hospitals and the correlation between resistance characteristics and
their biofilm-forming capacity.
15Methods: A total of three hundred (n=300) S. aureus isolates (corresponding to MSSA and
MRSA isolates in equal measure) were included in this study. Identification of the isolates©was
carried out using the VITEK 2 ID/AST system and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS). Antimicrobial susceptibility testing was
performed using the Kirby–Bauer disk diffusion method and E-tests, confirmation of MRSA
20status was carried out using PBP2a agglutination assay. Biofilm-production was assessed using
the crystal violet (CV) tube-adherence method and the Congo red agar (CRA) plate method.
Results: There were significant differences among MSSA and MRSA isolates regarding
susceptibility-levels to©commonly used antibiotics (in case of erythromycin, clindamycin and
ciprofloxacin: p<0.001, gentamicin: p=0.023, sulfamethoxazole/trimethoprim: p=0.027, rifam-
25pin: p=0.037). In the CV tube adherence-assay, 37% (n=56) of MSSA and 39% (n=58) of
MRSA isolates were positive for biofilm-production, while during the use of CRA plates, 41%
(n=61) of MSSA and 44% (n=66) of MRSAwere positive; no associations were found between
methicillin-resistance and biofilm-production. On the other hand, erythromycin, clindamycin
and rifampin resistance was associated with biofilm-positivity (p=0.004, p<0.001 and p<0.001,
30respectively). Biofilm-positive isolates were most common from catheter-associated infections.
Discussion: Our study emphasizes the need for additional experiments to assess the role
biofilms have in the pathogenesis of implant-associated and chronic S. aureus infections.
Keywords: Staphylococcus aureus, MSSA, MRSA, biofilm, antibiotic resistance, crystal
violet, Congo red agar, phenotypic assay
Introduction
35Staphylococcus aureus (S. aureus) is a Gram-positive, catalase-positive and bacitra-
cin-resistant coccus, which is a common colonizer of the human body. These bacteria
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and moist regions of the skin (eg, axilla, groin and
perineum).1,2 According to recent data, 60% of the popula-
40 tion is transiently colonized, while in 30%, this colonization
is persistent.3 S. aureus (both MSSA [methicillin-sensitive
S. aureus] and MRSA [methicillin-resistant S. aureus]) is an
exceptionally successful and adaptable pathogen, relevant in
both community-associated and nosocomial infections.4
45 They are an important cause of skin and soft tissue infec-
tions (SSTIs), osteoarticular infections, medical device-
related infections, pneumonia, infective endocarditis and
bacteremia (in addition, through hematogenous spread,
this microorganism may cause a wide range of secondary
50 pathologies).5,6 MRSA was first identified in 1961 and has
emerged as the first multidrug-resistant (MDR) bacterium in
human medicine.7 MRSA is resistant to all β-lactam anti-
biotics (with the exception of©fifth-generation cephalospor-
ins), severely narrowing safe and effective treatment
55 options; additionally, these strains often possess a battery
of resistance-determinants against other antibiotic groups
(eg, fluoroquinolones, macrolides, tetracyclines, aminogly-
cosides), thus earning the name “superbug” for the first
time.8 Methicillin-resistance is mediated by modifications
60 in penicillin-bindings proteins (namely PBP2a/2c/2ʹ), owing
to the presence of mecA or mecC genes. Initially, MRSA
was mainly associated with nosocomial infections (hospital-
associated MRSA; HA-MRSA), however, some 20–30
years after its initial description, community-associated
65 MRSA (CA-MRSA) infections have also emerged.4,9
Since the 2000s, extensive research regarding livestock-
associated MRSA (LA-MRSA) has been published, both
due to its impact in veterinary medicine (for animal hus-
bandry and for companion animals) and due to the possible
70 relevance of animals as vectors for MRSA transmission.10
The prevalence of MRSA infections shows large geogra-
phical differences: it is around 1–10% in Northern Europe,
15–30% in the United States, 40–50% in Southern and
Eastern Europe, while it may exceed 80% in some parts
75 of Asia.11 Risk factors associated with acquiring an MRSA
infection©include advanced age (≥60 years), prolonged hos-
pital stay, prior antimicrobial treatment and the use of
nasogastric tubes or endovascular catheters.12 MRSA infec-
tions are associated with decreased quality of life (QoL),
80 excess mortality and substantial economic costs, compared
to MSSA infections.4,12
The emergence of MDR isolates in human infections
considerably limits clinicians in administering adequate
antimicrobial therapy.13,14 A variety of resistance-
85 determinants have been described in the literature (both
intrinsic resistance and genes acquired on mobile genetic
elements), allowing bacteria to withstand otherwise lethal
doses of antibiotics.15 In addition to these resistance-
determinants, the production of biofilms by bacteria is
90another important factor leading to treatment failures.16
The first record on the existence of bacterial biofilms
was published by Henrici (1933), while a recent publica-
tion by the National Institute of Health (NIH) suggested
that in in vivo AQ6conditions, 60% of all infections are caused
95by bacteria embedded in biofilms.17,18 Biofilms are aggre-
gates of mono-species or multispecies bacterial commu-
nities, enveloped in a protective extracellular matrix.19,20
This matrix is typically made up of secreted exopolysac-
charides (EPS), environmental DNA (eDNA), proteins,
100surfactants, lipids and water.21 Biofilms allow bacterial
communities to attach to and persist on inanimate surfaces
and inside the body. The initial step of biofilm-production
is the attachment of bacteria to relevant surfaces (most
commonly coarse or hydrophobic surfaces, such as cathe-
105ters, implanted medical devices and other biomaterials),
with the aid of EPS, surface proteins, fimbriae and pili.22
After the development of the mature biofilm, bacteria
residing inside this protective structure will be in different
metabolic states: bacteria in the surface layer of the bio-
110film will be aerobic and©metabolically active; while in the
deeper layers, due to nutrient deficiency and lower oxygen
concentrations, bacteria are fermentative and dormant.23 In
essence, biofilms provide double protection against anti-
biotics: as most antibiotics are only effective against
115actively-replicating (ie, planktonic) cells, the eradication
of these persisters is an important challenge; additionally,
the thick biofilm also©acts as a pharmacokinetic barrier,
limiting the diffusion of antimicrobials and other noxious
agents in the vicinity of the pathogens.24,25 This may result
120in minimal inhibitory concentrations (MICs) 10–10,000-
times higher against bacteria embedded in biofilms.26
Owing to this resistance against antibiotics and the protec-
tive effects of biofilms against harsh environmental stres-
sors (eg, sheer forces, drying) and the immune system (eg,
125phagocytosis), it is unsurprising that biofilms are an
important virulence factor in the development of skin
and soft tissue infections, catheter- (intravascular or urin-
ary) and medical device-associated infections, oral infec-
tions, dental caries and chronic infections.27–30
130At present, the group of “ESKAPE” bacteria – which is
a list©consisting of MDR pathogens, including MRSA – is
considered as the most concerning in respect to their
resistance rates, clinical impact and mortality.31 As most
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of the ESKAPE-members are biofilm-producers, there has
135 been significant interest in assessing the possible relation-
ship between their MDR status and the biofilm-producer
phenotype.32 Although several studies have provided
experimental data on the subject, corresponding to both
MDR and wild-type Gram-negative (eg, Escherichia
140 coli,33 Klebsiella spp.,34 Pseudomonas aeruginosa,35
Acinetobacter spp.36) and Gram-positive bacteria (eg,
MSSA/MRSA,37 Enterococcus spp.38), the findings of
these studies are often controversial. With this in mind,
the aim of our present study was to assess the rates of
145 biofilm-production in various clinical MSSA and MRSA
isolates from Hungarian©hospitals with phenotypic meth-
ods, and the potential correlation between the resistance
characteristics and their biofilm-forming capacity.
Materials and Methods
150 Collection of Isolates
A total of three hundred (n=300) S. aureus isolates (corre-
sponding to MSSA and MRSA isolates in equal measure;
n=150 isolates, respectively) were included in this study,
which were kindly provided by a tertiary-care teaching
155 hospital and two smaller regional hospitals in Hungary.
The study uses a cross-sectional study design; the microor-
ganisms were isolated between 2019.01.01©and 2020.01.01.,
including n=100 isolates from catheter-associated infections
(CAI-SA), skin and soft tissue infections (SSTI-SA) and
160 urinary tract infections (UTI-SA). During our experiments,
S. aureus ATCC 29213 (MSSA; positive for biofilm-
production, icaAB gene negative), S. aureus ATCC 43300
(MRSA; positive for biofilm-production, icaAB gene posi-
tive), S. aureus ATCC 12600 (MSSA; non-biofilm produ-
165 cing, icaAB gene negative), S. epidermidis ATCC 35984
(positive for biofilm-production, icaAB gene positive) and
S. epidermidis ATCC 12224 (non-biofilm producing, icaAB
gene negative) were used as control strains, obtained from
the American Type Culture Collection (ATCC; Manassas,
170 VI, USA).39 Stock cultures were stored at −80 °C in
a cryopreservation medium (700 µL trypticase soy broth +
300 µL 50% glycerol).
Bacterial Identification
Identification of S. aureus isolates was carried out using
175 the VITEK 2 ID/AST automated system (bioMérieux,
Marcy-l’Étoile, France) and matrix-assisted laser deso-
rption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS; Bruker Daltonics, Bremen,
Germany). During the MALDI-TOF assay, bacterial cells
180from fresh overnight cultures were transferred to
a stainless-steel target. An on-target extraction was per-
formed by adding 1 µL of 70% formic acid prior to the
matrix. After drying at room temperature, the cells were
covered with 1 µL matrix (α-cyano-4-hydroxy cinnamic
185acid in 50% acetonitrile/2.5% trifluoro-acetic acid; Bruker
Daltonics, Bremen, Germany). Mass spectrometry ana-
lyses were performed by the Microflex MALDI Biotyper
(Bruker Daltonics, Bremen, Germany) in positive linear
mode across the m/z range of 2 to 20 kDa; for each
190spectrum, 240 laser shots at 60 Hz in groups of 40 shots
per sampling area were collected. The MALDI Biotyper
RTC 3.1 software (Bruker Daltonics, Bremen, Germany)
and the MALDI Biotyper Library 3.1 were used for spec-
trum analysis. As a result of the MALDI-TOF spectrum
195analysis, a log(score) value was provided, indicating the
reliability of MALDI-TOF MS identification. The log-
(score) values were evaluated as follows: a log(score)
<1.69 showed unreliable identification, 1.70–1.99 cor-
responded to probable genus-level identification, 2.00–-
2002.29 corresponded to reliable genus-level identification,
while a score ≥2.30 corresponded to reliable species-
level identification.40 All isolates included in the study
were re-identified as S. aureus before further experiments.
Antimicrobial Susceptibility Testing,
205Resistance Detection
Antimicrobial susceptibility testing (AST) was performed
either using the Kirby–Bauer disk diffusion method or
E-tests (Liofilchem, Teramo, Italy) on Mueller–Hinton
agar (MHA) plates. During testing, the susceptibilities to
210erythromycin (ERY; 15 µg), clindamycin (CLI; 2 µg),
ciprofloxacin (CIP; 5 µg), gentamicin (GEN; 10 µg), sul-
famethoxazole/trimethoprim (SXT; 23.75/1.25 µg), vanco-
mycin (VAN; E-test), tigecycline (TIG; 15 µg), linezolid
(LZD; 10 µg), fusidic acid (FUS; 10 µg),©quinupristin/
215dalfopristin (QDP; 15 µg), rifampicin (RIF; 5 µg) and
ceftaroline (CFT; 5 µg) were determined. Interpretation
of testing results and classification of isolates as MDR
(being non-susceptible to at least one antimicrobial agent
in three or more antimicrobial classes) was based on
220EUCAST standards and breakpoints v. 9.0. (http://www.
eucast.org). VITEK 2 ID/AST (bioMérieux, Marcy-
l’Étoile, France) was used for the verification of discrepant
results. During data analysis, intermediate results were
grouped with and reported as resistant. Inducible CLI
Infection and Drug Resistance 2021:14 submit your manuscript | www.dovepress.com
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225 resistance was detected using the ERY-CLI D test; these
strains were also reported as resistant.41
Methicillin-resistance was verified using mannitol salt
agar (MSA) plates using cefoxitin (FOX) disks (zone
diameters under 22 mm were considered positive for
230 methicillin-resistance) and PBP2ʹ Latex Agglutination
Test (Thermo Fisher Scientific Hungary GmbH,
Budapest, Hungary). A MRSA strain was automatically
considered to be resistant to all β-lactam antibiotics other
than CFT.41 MSSA S. aureus ATCC 29213 and MRSA
235 S. aureus ATCC 43300 were used as quality control
strains.
Detection of Biofilm-Production by the
Tube-Adherence Method
Assessment of biofilm-formation was carried out in the
240 tube-adherence method described previously.42 In short,
glass tubes containing 1 mL of sterile trypticase soy
broth (bioMérieux, Marcy-l’Étoile, France) were inocu-
lated with 1 µL of the overnight culture of a respective
bacterial strains. Respective tubes were then incubated
245 statically for 24 h at 37 °C. Verification of planktonic
growth was observed visually. After the incubation period,
the supernatant was then discarded, the adhered cells were
rinsed three times with phosphate buffer saline (PBS;
Sigma-Aldrich; Budapest, Hungary) and the tubes were
250 patted dry on a paper towel. The contents of the tubes
were treated with a 1 mL solution of 0.1% crystal violet
(CV; Sigma-Aldrich; Budapest, Hungary) to stain the
adhered biomass; the tubes were incubated for 3 h at
room temperature with the staining solution. The CV
255 solution was then discarded and the tubes were again
rinsed three times with PBS and the tubes were patted
dry on a paper towel. Biofilm-formation was observed
visually; in case of the appearance of visible biofilm lining
at the bottom and on wall of the glass tubes, the strain was
260 considered a biofilm-producer in this assay.33,42 All experi-
ments were performed in triplicate and were evaluated by
two independent researchers.
Detection of Biofilm-Production by the
Congo Red Agar Method
265 Biofilm-formation of the isolates©was also evaluated on
Congo Red Agar (CRA) plates, based on the previously
described protocol.43 Briefly, CRA plates were prepared
using trypticase soy agar supplemented with 5% sucrose
and 40 μg/mL Congo red dye (Sigma-Aldrich; Budapest,
270Hungary). Congo red is a secondary diazo dye, which can
be used as a pH indicator (with a detectable color change
at pH 3.0–5.2). Strains were cultured on trypticase soy
agar plates at 37 °C for 16–©18 h; cells were resuspended
in trypticase soy broth at a density of OD600=2;©10 µl of
275the suspension was spotted on CRA plates. The inoculated
CRA plates were incubated at 37 °C in aerobic conditions
for 24 h, followed by incubation at room temperature
before the reading of the plates for an additional 24
h. The isolates were assessed for their colony-
280morphologies: black colonies with a dry consistency and
rough surface edges were considered as biofilm-producers
in this assay, while red colonies with smooth, round and
shiny surface were read as negative for biofilm-
production.43 All experiments were performed in triplicate
285and were evaluated by two independent researchers.
Statistical Analysis
Descriptive statistical analysis (including means and per-
centages to characterize data) was performed using
Microsoft Excel 2013 (Microsoft Corp.; Redmond, WA,
290USA). Additional statistical analyses were performed with
IBM SPSS Statistics for Windows 24.0 (IBM Corp.,
Armonk, NY, USA), using the χ2-test.44 p values©<0.05
were considered statistically significant. Additionally, con-
sistency-assessment was also performed between the
295results of the two different biofilm-production studies
(CV assay vs CRA agar).30
Ethical Considerations
Clinical, personal and epidemiological data pertaining to
the affected patients were not collected or provided during
300the study, bacterial isolates were only identifiable based on
their serial number; therefore, our present study was not
subject to ethics review.
Results
Antibiotic Susceptibility of MSSA and
305MRSA Isolates Included in the Study
Out of the tested S. aureus isolates, the following suscept-
ibilities were detected overall: complete susceptibility
(100%; n=300) was seen for VAN, CFT, QDP, FUS,
LZD and TIG 100%; on the other hand, varying levels of
310resistance were observed for other antibiotics, such as
GEN 90% (n=271), SXT 89% (n=268), RIF 86%
(n=257), ERY 54% (n=162), CIP 51% (n=153) and CLI
48% (n=144). The detailed susceptibilities for every group
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2021:144
Senobar Tahaei et al Dovepress
of isolates (namely CAI-SA, SSTI-SA and UTI-SA) are
315 presented in Table 1. There were significant differences
among MSSA and MRSA isolates regarding susceptibil-
ity-levels to©commonly used antibiotics (ERY: p < 0.001,
χ2 = 156.52, degrees of freedom [DOF]: 1; CLI: p < 0.001,
χ2 = 155.63, DOF: 1; CIP: p < 0.001, χ2 = 192.03, DOF: 1;
320 GEN: p < 0.023, χ2 = 12.03, DOF: 1; SXT: p = 0.0027, χ2
= 8.95, DOF: 1; RIF: p = 0.0037, χ2 = 8.95, DOF: 1).
Similarly, the subset of MRSA isolates could be classified
as MDR more commonly (85% [n=128] vs 8% [n=12]),
compared to isolates from the MSSA group.
325 Association of MSSA/MRSA Status and
Resistance to Other Antibiotics with
Biofilm-Production
In the CV tube adherence-assay, 37% (n=56) of MSSA and
39% (n=58) of MRSA isolates were positive for biofilm-
330 production, while during the use of CRA plates, 41% (n=61)
of MSSA and 44% (n=66) of MRSAwere positive; no asso-
ciations were found between methicillin-resistance and bio-
film-production (p>0.05 in both cases). The agreement
between the results of the two phenotypic testing methods
335 was 0.897 (89.7%) overall (91.8% in case of MSSA and
87.8% in case of MRSA isolates). Interestingly, biofilm-
production was more commonly detected from both MSSA
and MRSA CAI-SA isolates (p<0.0001 and p=0.0018 for
MSSA, p=0.02 and p=0.015 for MRSA, respectively), com-
340 pared to the isolates from other origins. The detailed distribu-
tion of biofilm-positive S. aureus among the isolates of
different origin, the results of the statistical analyses and the
agreements among the CV adherence assay and CRA plates
are presented in Figure 1. Among the control strains, S. aureus
345 ATCC 29213, S. aureus ATCC 43300, S. epidermidis ATCC
35984 were positive for biofilm-production in both phenoty-
pic assays, while S. aureus ATCC 12600 and S. epidermidis
ATCC 12224 were both negative.
The relationship between biofilm-production and resis-
350 tance to other antibiotics was also assessed; during these
analyses, only the results from the CRA plates were consid-
ered. It was found that resistance to ERY (p = 0.004, χ2 = 8.12,
DOF: 1), CLI (p < 0.001, χ2 = 44.57, DOF: 1) and RIF (p <
0.001, χ2 = 96.95, DOF: 1) was associated with biofilm-
355 positivity; in fact, 37 out of 43 (86%) of RIF-resistant isolates
were biofilm-producers. On the other hand, this association
was not shown for other antibiotics (ie, CIP, GEN, SXT;
p>0.05).
Discussion and Review of the
360Literature
S. aureus infections are associated with considerable mor-
bidity, mortality and economic costs for the healthcare
institutions worldwide.45 Owing to the adaptability, the
plethora of virulence factors and the increasing levels of
365antimicrobial resistance in S. aureus, treatment of these
infections is a considerable challenge for clinicians.46
Biofilm-formation has been classified as an important
defense mechanism and pathogenic hallmark for both
MSSA and MRSA isolates, both as a means to persist in
370the environment (eg, on a hospital ward) and in the host
during infections.47 It has been described that the staphy-
lococcal colonization of the skin is dependent of the bio-
film-formation of these bacteria; in addition, S. aureus
strains adhere to damaged skin and mucosal surfaces
375more easily, leading to the development of SSTIs.48 At
the same time, all inserted and implanted medical devices
(contact lenses, cardiac pacemakers, prosthetic valves,
cerebrospinal fluid shunts, implanted catheters and syn-
thetic joints) are at risk to be associated with S. aureus
380infections (eg, endocarditis, osteomyelitis, bacteremia).49
In the present study, we have investigated n=150 MSSA
and n=150 MRSA isolates – originating from clinical
materials – regarding their antibiotic susceptibilities and
their biofilm-forming capacities using two phenotypic
385tests, namely the CV tube-adherence assay and the plate-
based CRA medium. There are a plethora of methods
available for the characterization of the biofilm-forming
capacity of bacteria – self-developed and chromogenic
media (both in liquid and in plate form), staining methods,
390assessment via measurements with a spectrophotometer or
electron microscopy and most recently, flow chamber sys-
tems – however, these are pronounced differences among
these methods in the price, reproducibility, high-
throughput nature and the in vivo adaptability of the
395results.50–52 Our two utilized methods have been described
for a number of years (the CV tube-based assay was
described by Christensen et al in 1982,53 while the CRA
method was developed by Freeman et al in 1989);54
although subsequent studies have demonstrated that these
400methods needed to be modified to improve accuracy and
sensitivity, these methods are cheap, easy to perform, the
criteria for their evaluation©are straightforward and their
results are comparable to other, more expensive assays.39
In our study, no significant association was noted between
405MSSA/MRSA-status and biofilm-production in either
Infection and Drug Resistance 2021:14 submit your manuscript | www.dovepress.com
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phenotypic tests; however, ERY, CLI and RIF resistance
was more common in biofilm-producing S. aureus isolates.
It is also interesting to note that 86% of isolates resistant to
RIF were biofilm-producers, especially as RIF is consid-
410 ered an effective antimicrobial agent with good penetration
into bacterial biofilms in vivo.55 Although the exact reason
behind this phenomenon is unknown, it has been described
that the sub-inhibitory concentrations of several antibiotics
may induce biofilm-formation in S. aureus isolates.56
415 Interestingly, the interplay between sub-inhibitory doses
of antibiotics has been most frequently published in rela-
tion to the MLKS (macrolide-lincosamide-ketolide-©
streptogramin; which are all protein synthesis inhibitors
affecting the 50S ribosome) group of drugs and rifampin.57
420For example, Lima-e-Silva et al reported that in sub-lethal
doses (MIC/2 and MIC/4), rifampin strongly stimulated
biofilm-formation (when measured by the CRA plate and
CV microtiter plate assay), in contrast to minocycline,
which did not have such inducing effects.58 The effects
425of low antibiotic doses on the biofilm-forming capacity are
thought to occur by differential expression of genes of
interest due to the noxious agents.59 The literature has
shown that sub-MIC concentrations of tetracycline,
©quinupristin and dalfopristin were presented as strong
430inducers, while erythromycin was noted as a weak inducer
of ica-gene expression. In contrast, gentamicin, chloram-
phenicol (which are also protein synthesis inhibitors),
penicillin, oxacillin, ofloxacin and vancomycin did not
Figure 1 Antibiotic susceptibility rates among S. aureus isolates included in this study.AQ7
Abbreviations: MSSA, methicillin-resistant S. aureus; MRSA, methicillin-resistant S. aureus; CAI-SA, catheter-associated infections; SSTI-SA, skin and soft tissue infections;
UTI-SA, urinary tract infections.
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present with similar effects.60 The clinical origin of the
435 isolates also had an effect on their biofilm-producing
capacity: they were the most prevalent in isolates from
catheter-associated infections and the least common in
strains isolated from the urinary tract. Finally, the agree-
ment among the results of the two in vitro methods was
440 89.7%, which is a very good result, based on other studies
from the literature.39
Many studies have aimed to assess the correlation of
biofilm-production with antibiotic-resistance in S. aureus
strains; nevertheless, the literature©has shown conflicting
445 data on the topic, thus, at present, we are unable to draw
far-reaching conclusions. To make the interpretation of the
currently available results even more troublesome, many
different methodologies have been used to assess biofilm-
formation, with or without the molecular characterization
450 of the isolates. Similarly to our results, Arslan et al found
no association between slime production and methicillin-
resistance or resistance to other antibiotics in a sample of
n=187 S. aureus isolates; in their report, CRA plates and
the CV tube adherence assay©were utilized, while molecu-
455 lar testing (for clonality or the presence of agr genes) was
not performed.61 Ghasemian et al assessed biofilm-
production in n=209 S. aureus isolates, among which no
relevant differences were shown for biofilm-positive and
negative isolates, based on methicillin-resistance (36.1%
460 and 28.9% for MRSA and MSSA, respectively). The
extent of biofilm-production was assessed by a microtiter
plate biofilm assay, and the genetic testing of the isolates
was also performed: 58.3% and 22.0% of isolates
belonged to the agr groups I and II, respectively, while
465 84.0% of MRSA isolates possessed the SCCmec III
cassette.62 Rodríguez-Lopez et al came to similar conclu-
sions, when studying S. aureus isolates originating from
animal and environmental samples at heavy swine farms in
Italy. In this report, the same methodology was utilized
470 (plate-based quantitative measurements), and spa-typing
was also performed: overall, isolates belonging to the
ST398/t899 and ST398/t011 were the most common
among biofilm-producers.63 El-Nagdy et al detected bio-
film-forming S. aureus (using the CRA plate method,
475 complemented with scanning and transmission electron
microscopy) from febrile neutropenic patients in Egypt;
interestingly, they have found that 72.7% of isolates were
biofilm-positive. Among the tested strains, 37.5% were
positive for icaA, and 22.9% were positive for icaD;
480 however, only 50% of biofilm-producers carried either
the icaA or icaD genes.64 Similarly, no correlation
among methicillin-resistance and biofilm-production was
seen in the reports of Knobloch et al (including n=128 ica-
positive isolates, with utilizing CRA plates and the micro-
485titer plate method)65 and Mathur et al (where n=152
Staphylococcus spp. were tested using the microtiter
plate method).66
However, there have been studies that identified differ-
ences in the rates of biofilm-production based on the
490phenotypic resistance of S. aureus isolates. In the study
by Bose et al (in which the authors have utilized similar
methodologies to our study, in addition to the tissue cul-
ture plate method to quantify their results) found higher
levels of antibiotic resistance in biofilm-producing
495S. aureus and S. epidermidis isolates.67 Piechota et al
compared the biofilm-forming capacity of MSSA and
MRSA isolates from Poland: in this report, MRSA isolates
were stronger biofilm-producers overall in the microtiter
plate-based assay (39.7% vs 36.8%) and the occurrence of
500icaABCD genes (51.5% overall) was also more common in
methicillin-resistant strains.68 Cha et al characterized
n=126 MRSA isolates from a Korean teaching hospital,
during which they have found higher levels of MDR iso-
lates (defined as MRSA+resistance to at least three non-β-
505lactam agents) among the biofilm-forming isolates. The
study group has used the microtiter plate assay to quantify
biofilm-formation and has also performed molecular test-
ing: they have shown that the majority of the isolates were
ST5 (69.8%) and 64.0% of isolates are from the agr group
510II.69 Souli et al©have clearly demonstrated that strong
biofilm-producers (tested with the CV tube-based assay)
among S. epidermidis isolates had also possessed higher
levels of resistance in vitro.70 Agarwal and Jain tested
commensal, colonizing and invasive S. aureus isolates
515for their biofilm-forming capacity using the microtiter
plate assay; in their study, biofilm-producers were more
frequently MDR in all groups, and 94.0% of biofilm-
producers carried ica-genes.71 De©Araujo et al reported
that methicillin-resistant and MDR S. epidermidis isolates
520were more frequent among biofilm-producers (tested by
the microtiter plate assay). They have found that 96.0% of
biofilm-positive isolates carried icaA or icaD genes, while
86.0% were positive for atlE and aap genes.72 In contrast,
in a report concerning S. aureus isolates originating from
525pork, Zhang et al found 83.8% of the bacteria to be agr-
positive (agr I: 39.2%, agr IV: 32.3%) and noted the high
prevalence of MDR isolates in moderate and weak bio-
film-producers, when tested with the microplate method.73
Our study demonstrated an association of CLI-resistance
submit your manuscript | www.dovepress.com
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530 and biofilm-production corresponding to our isolates,
which has been identified in other reports as well, although
these studies usually also showed a positive correlation
with methicillin-resistance. In the study by Belbase et al,
S. aureus isolates from pus/wound swab samples were
535 assessed for the susceptibility and microtiter-based bio-
film-production in a tertiary-care hospital in Nepal.
Overall, methicillin-resistance and inducible CLI-
resistance©were more common in biofilm-producers.
38 In
another study from Nepal, Manandhar et al also showed
540 that the in vitro biofilm-production (assessed by CRA
plates) of S. aureus isolates was associated with methicil-
lin-resistance and inducible CLI-resistance.74 Bhattacharya
et al tested n=100 S. aureus isolates, including 47%
MRSA isolates: biofilm-positivity was shown in 55.0%
545 of isolates, with MRSA isolates in higher numbers
among biofilm-producers; in addition, resistance-levels
against CIP, RIF, ERY, CLI and SXT were also signifi-
cantly higher in biofilm-positive isolates.75 Finally,
Neopane et al tested n=150 S. aureus isolates, originating
550 from pus samples: in their study – although no clear
association was seen with methicillin-resistance and bio-
film-production, strong biofilm-production and the MDR
status has shown good agreement.76 In the latter three
studies, only phenotypic characterization of resistance
555 and biofilm-production©was utilized. Overall, the literature
findings suggest a possible relationship between the
expression of antibiotic-resistance-determinants and bio-
film-production, however, the clarification of nature of
this association will require further studies.
560 Pulse-field gel electrophoresis (PFGE) and multi-locus
sequence typing (MLST)©are not routinely performed in
Hungary by diagnostic laboratories; thus, there is
a scarcity of local data regarding the molecular epidemiol-
ogy of S. aureus isolates, such data may be sourced from
565 major national public health surveillance studies: the
Hungarian clone (ST239-III, PFGE type E) – which was
predominant before 2000 – was almost completely
replaced by the Southern German clone (ST228-I, PFGE
type B) and the New York/Japan epidemic clone (ST5-II,
570 PFGE type A/C), and since 2006, the breakthrough of the
EMRSA-15 (ST22-IV, PFGE type D) was described.77
Based on the most recent data (2017–2018) available
from the National Institute of Public Health in Hungary,
~45% of HA-MRSA isolates were ST22-IV clones, while
575 ~24% of isolates were ST5-II; in case of CA-MRSA iso-
lates, ST8-IV and ST80-IV clones were the most common,
while among LA-MRSA, CC398 isolates were the most
prevalent.78,79 Literature data also©suggest that the clonal
background of S. aureus isolates may play a major role in
580the biofilm-forming capacity, however (as demonstrated
by the publications discussed in the previous section), the
clonality of the isolates is seldom reported in these
studies.80 Croes et al reported that S. aureus isolates
from MLST clonal complex CC8 were the most potent
585biofilm-producers – irrespective of the glucose-
concentration (0–0.5%) in the media; at physiological
glucose (0.1%) concentration, >60% of CC8 isolates
were strong biofilm-producers, compared to 0–7% in
other tested CCs.81 These findings were also supported
590by the results of Luther et al: from n= 182 clinical
MRSA strains, isolates belonging to the CC8 group and
spa type t008 group were significantly more common
among strong biofilm-producers (p=0.01), while spa type
t895 and β-toxin-producing isolates showed a negative
595correlation with biofilm-production.82 The study of
Recker©et al performed combined study, including labora-
tory assays and a data analysis regarding bacterial geno-
type and phenotype with available clinical metadata in
a machine-learning framework, corresponding to n=300
600S. aureus, including CC22 and CC30 isolates from bacter-
emia. Their results showed no relevant differences in bio-
film-formation among MSSA and MRSA isolates or
among CC22 and CC30 isolates. Although this report
showed no association with biofilm-production and
605SCCmec-type, other studies highlighted that the SCCmec
II element is associated with decreased capability to form
biofilm.83 On the other hand, Lim et al (who assessed
n=465 clinical S. aureus isolates) and da Fonseca
Batistao (during the study of fifteen isolates) both con-
610cluded that the presence of the SCCmec III cassette is
a good predictor of strong biofilm-forming ability.84,85
The importance of the SCCmec cassette and mecA genes
in biofilm formation were highlighted by Pozzi et al,
where ΔSCCmec (deletion mutants) presented with
615decreased expression of virulence determinants, including
biofilms; the authors of the study have concluded that
these genes may have the potential to affect phenotypic
characteristics mediated by other operons (ie, agr or
icaADBC) to facilitate the adaptation of hospital-
620associated MRSA to the harsh environment in
hospitals.86 This may be the reason for the larger number
of biofilm-producing isolates from catheter-associated
(CAI-SA) infections.
It has been described that S. aureus strains usually
625form multilayered biofilms; this biofilm is useful in the
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evasion of the non-specific and adaptive immune
responses of the host, including decreased rate of opsoni-
zation, phagocytosis, killing by neutrophil granulocytes,
and Toll-like receptor activation.87,88 The latter is particu-
630 larly relevant, because TLR-activation is important in
facilitating a Th2-type immune response, which may act
to prevent S. aureus biofilm-associated infections.89
Biofilms are also protective against reactive oxygen spe-
cies (ROS) in in vivo environments.90 Biofilms also facil-
635 itate the metabolic transformation of S. aureus into the
small colony variant (SCV; which may be seen as “dwarf
colonies” on solid media) morphotype: in this sub-
population, bacteria exist at a lower metabolic activity
(leading to increased antimicrobial resistance), which
640 also enables in vivo persistence and chronic infections.91
In addition to metabolic switching, SCVs are also charac-
terized by adaptation for intracellular survival in mamma-
lian cells, where the pathogen acts similarly to other
microorganisms with a strictly intracellular life cycle.92,93
645 The relevance of eDNA in the stability and antimicrobial
resistance of staphylococcal biofilms has been demon-
strated, as DNase treatment (eg, in cystic fibrosis) clearly
negatively impacts the biofilm structure.94 Biofilm-
formation in S. aureus is©genetically mediated by the
650 regulatory genetic locus staphylococcal accessory regula-
tor (sarA); this controls two pathways – namely the intra-
cellular adhesin (ica) operon and accessory gene regulator
(agr) regulated pathways – both of which have been sug-
gested as determinants of the extent of biofilm-formation
655 in these bacteria.95,96 The product of the genes of the ica
operon (icaADBC) are the IcaA and IcaD transferase
membrane proteins; these proteins have important roles
in the biosynthesis of PIA (polysaccharide intercellular
adhesion protein; or poly-β-1,6-©N-acetylglucosamine
660 [PNAG]), which is a major component of staphylococcal
biofilms.97 Although our study did not demonstrate pro-
nounced differences among the biofilm-producing capabil-
ities of the©locally collected MSSA and MRSA isolates,
there have been studies offering possible biological expla-
665 nations to this phenomenon.38 It has been suggested that
biofilm-formation in MSSA is mediated by cell-cell adhe-
sion via the production of PIA (encoded by icaADBC),
while MRSA biofilm-production is PIA-independent, and
rather, it is dependent on a protein adhesion, which is
670 negatively regulated by the agr system.98,99 O’Neill et al
showed that media supplementation with NaCl results in
the induction of biofilm-production in MSSA only, as this
activated the expression of the ica operon.100 In contrast,
Croes et al showed that the presence of excess glucose in
675the media represses the agr system (through the generation
of low pH), which resulted in the induction of biofilm-
production in MRSA only;81,101 additionally, the deletion
of the agr system also enhanced the biofilm-production of
MRSA isolates, while it had no effect on its methicillin-
680susceptible counterparts.102
Conclusions
The production of biofilm by pathogenic bacteria in vivo
provides important protection from external forces and
antimicrobials, in addition to facilitating chronicity.
685S. aureus is an©exceptionally adaptable pathogen both
in natural environment and in clinical situations. Biofilm-
formation in both MSSA and MRSA isolates is an impor-
tant step in the pathogenesis of implant-associated
infections©and leads to a synergistic interaction between
690“classical” resistance-determinants and the inability of
antibiotics and immune cells to reach S. aureus isolates.
The relationship between the MDR phenotype and bio-
film-positivity has been studied for many relevant patho-
gens, however, the culmination of these results ©is
695inconclusive. In our study, one hundred and fifty MSSA
and one hundred and fifty MRSA isolates (from a variety
of clinical situations) were tested for their antibiotic-
susceptibility and their biofilm-forming capacity to ascer-
tain a possible relationship between the two. Among our
700tested isolates, we have found complete susceptibility to
the last-resort agents, while there were significant differ-
ences in the resistance rates between MSSA and MRSA
isolates regarding almost all other, commonly used
agents.©Thirty-eight percent and 42% of isolates were
705biofilm-producers based on the CV tube adherence
assay and the CRA plate methods, respectively. Overall,
no association was found between methicillin-resistance
and biofilm-positivity in our settings; on the other hand,
resistant isolates to erythromycin, clindamycin and
710rifampin were significantly more common among bio-
film-producers.
Our study possesses some limitations: i) the©cross-
sectional nature of the study: although isolates were collected
from different clinical specimen groups, they may not repre-
715sent Hungarian S. isolates, their biofilm-forming capacity or
susceptibility overall; ii) selection bias: isolates usually ori-
ginated from tertiary-care centers, corresponding to patients
with more severe conditions or underlying illnesses; iii)
interpretation: both phenotypic methods were evaluated by
720organoleptic methods, therefore the reading of the results was
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dependent on the expertise of the researchers; iv) lack of
molecular methods: the molecular characterization of resis-
tance determinants, clonal lineages (with PFGE or MLST) or
genetic determinants of biofilm-production (eg, agr, ica
725 genes) in the mentioned isolates was not performed.
Nevertheless, our study provides additional data to the exist-
ing pool of literature on the association of drug resistance and
biofilm-formation in S. aureus. Additional studies – with the
inclusion of other isolates and utilization – are needed to
730 provide clarity on this subject.
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